Stockholm - Delayed Quote SEK

Spago Nanomedical AB (publ) (SPAGO.ST)

Compare
0.2100
0.0000
(0.00%)
At close: January 10 at 3:10:57 PM GMT+1
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,025.0000
1,203.0000
1,054.0000
660.0000
342.0000
Cost of Revenue
17,327.0000
24,486.0000
16,658.0000
17,436.0000
758.0000
Gross Profit
-15,302.0000
-23,283.0000
-15,604.0000
-16,776.0000
-416.0000
Operating Expense
19,319.0000
19,222.0000
23,481.0000
22,291.0000
18,537.0000
Operating Income
-34,621.0000
-42,505.0000
-39,085.0000
-39,067.0000
-18,953.0000
Net Non Operating Interest Income Expense
1,093.0000
850.0000
268.0000
120.0000
34.0000
Pretax Income
-34,096.0000
-42,223.0000
-39,197.0000
-39,071.0000
-18,928.0000
Net Income Common Stockholders
-34,096.0000
-42,223.0000
-39,197.0000
-39,071.0000
-18,928.0000
Diluted NI Available to Com Stockholders
-34,096.0000
-42,223.0000
-39,197.0000
-39,071.0000
-18,928.0000
Basic EPS
-0.16
-0.43
-0.58
-0.95
-0.66
Diluted EPS
-0.16
-0.43
-0.58
-0.95
-0.66
Basic Average Shares
237,992.9490
97,978.0830
66,808.3700
41,262.3870
28,845.3620
Diluted Average Shares
299,185.9050
104,954.5880
67,188.7670
41,851.3680
29,442.4330
Total Operating Income as Reported
-35,189.0000
-43,073.0000
-39,465.0000
-39,192.0000
-18,962.0000
Total Expenses
36,646.0000
43,708.0000
40,139.0000
39,727.0000
19,295.0000
Net Income from Continuing & Discontinued Operation
-34,096.0000
-42,223.0000
-39,197.0000
-39,071.0000
-18,928.0000
Normalized Income
-34,096.0000
-42,223.0000
-39,197.0000
-39,071.0000
-18,928.0000
Interest Income
1,093.0000
850.0000
--
--
--
Net Interest Income
1,093.0000
850.0000
268.0000
120.0000
34.0000
EBIT
-34,621.0000
-42,505.0000
-39,085.0000
-39,067.0000
-18,953.0000
EBITDA
-34,309.0000
-42,224.0000
-38,729.0000
-38,691.0000
-18,591.0000
Reconciled Cost of Revenue
17,327.0000
24,486.0000
16,658.0000
17,436.0000
758.0000
Reconciled Depreciation
312.0000
281.0000
356.0000
376.0000
362.0000
Net Income from Continuing Operation Net Minority Interest
-34,096.0000
-42,223.0000
-39,197.0000
-39,071.0000
-18,928.0000
Normalized EBITDA
-34,309.0000
-42,224.0000
-38,729.0000
-38,691.0000
-18,591.0000
12/31/2020 - 1/16/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2CUREX.ST 2cureX AB (publ)
0.4200
0.00%
 
XINT.ST Xintela AB (publ)
0.3800
-5.47%
 
IMMU.ST Mendus AB (publ)
8.20
0.00%
 
GENO.ST Genovis AB (publ.)
24.65
+0.41%
 
SCPS Scopus BioPharma Inc.
0.0003
0.00%
 
ULTI.OL Ultimovacs ASA
2.1700
-3.56%
 
NXTCL.ST NextCell Pharma AB
2.8000
-1.41%
 
CUV.AX Clinuvel Pharmaceuticals Limited
11.54
+0.70%
 
HNSA.ST Hansa Biopharma AB (publ)
34.78
-0.69%
 
IDIA.SW Idorsia Ltd
0.7790
-1.77%